Im­metas Ther­a­peu­tics nabs $11M Se­ries A to nar­row their bis­pe­cif­ic work tar­get­ing in­flam­ma­tion in age-re­lat­ed dis­eases

How does a biotech cel­e­brate its two-year an­niver­sary? For Im­metas Ther­a­peu­tics, it’s with an $11 mil­lion Se­ries A round and a game plan to fight age-re­lat­ed dis­ease.

Co-founders Gene Wang and David Sin­clair came to­geth­er years ago around the idea that in­flam­ma­tion is the ul­ti­mate process dri­ving age-re­lat­ed ill­ness­es, in­clud­ing can­cer. The duo launched Im­metas in 2018 and packed the staff with in­dus­try ex­perts. Wang, who says he’s al­ways had an en­tre­pre­neur­ial spir­it, has held lead roles at No­var­tis, GSK, Bris­tol My­ers Squibb and Mer­ck. He’s worked on block­buster drugs like Hu­mi­ra, Gar­dasil, Varu­bi and Zolin­za. And now, he’s chan­nel­ing that spir­it as CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER